Company intelligence / Profile preview
iNtRON Biotechnology
Sungnam-si, Gyeonggi-do, SOUTH KOREAintronbio.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
iNtRON has several clinical-stage programs targeting bacterial infections with engineered endolysins and small molecules. Its lead assets include SML-200 and NFA-014 for streptococcal/Gram-negative infections. The company has outlicensed SAL200 to Roivant Sciences for further development. Diagnostic kits are already commercialized globally.
- Therapeutic areas
- ImmunologyNeurologyInfectious Diseases
- Modalities
- Bacteriophage therapyEndolysin-based biologicsSmall molecule drugsBiological products
- Industry
- Biotech
02
Drug pipeline
18 assets17 more assets in the full pipeline.
03
Partnerships
Roivant Sciences (SAL200 rights/license)various overseas distributors of diagnostics kits
Beyond the preview
Go deeper on iNtRON Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iNtRON Biotechnology.